Targeting liver cancer stem cells: the prognostic significance of MRPL17 in immunotherapy response.
Journal:
Frontiers in immunology
PMID:
39742265
Abstract
BACKGROUND: Liver hepatocellular carcinoma (LIHC) ranks as the foremost cause of cancer-related deaths worldwide, and its early detection poses considerable challenges. Current prognostic indicators, including alpha-fetoprotein, have notable limitations in their clinical utility, thereby underscoring the necessity for discovering new biomarkers to improve early diagnosis and enable personalized treatment options.